Gesynta Pharma AB

📍 Stockholm, Sweden🗓 Founded 2017👥 16 employees💰 Last funded May 2024
Pharmaceutical Manufacturing🌐 gesynta.se
Website LinkedIn
Gesynta Pharmas drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Gesynta Pharma AB?
Gesynta Pharma AB has 1 investors on record on gritt.io and 1 late-stage investors.
When did Gesynta Pharma AB last raise funding?
The most recent investment in Gesynta Pharma AB recorded on gritt.io was in May 2024.
When was Gesynta Pharma AB founded?
Gesynta Pharma AB was founded in 2017.
What industry is Gesynta Pharma AB in?
Gesynta Pharma AB operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Gesynta Pharma AB based?
Gesynta Pharma AB is headquartered in Stockholm, Sweden.